Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
/
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
DiaMedica Therapeutics Inc. is a clinical-stage biopharmaceutical company developing innovative therapies for serious vascular diseases driven by restricted blood flow and endothelial dysfunction. Its lead candidate, DM199, is a recombinant form of the human tissue KLK1 protein, designed to enhance blood flow and vascular health by increasing levels of nitric oxide, prostacyclin, and endothelium-derived hyperpolarizing factor. The company focuses on advancing DM199 for the treatment of preeclampsia, fetal growth restriction, and acute ischemic stroke, with ongoing clinical programs including Phase 2 investigator-sponsored trials and the ReMEDy2 Phase 2/3 trial. DiaMedica Therapeutics Inc. also explores applications in chronic kidney disease. Founded in 2000 and headquartered in Minneapolis, Minnesota, the company engages in clinical development, regulatory interactions, and corporate activities to address unmet needs in these critical therapeutic areas.
$6.15
$0.21 (-3.30%)
EOD Jun 25, 2026 · Twelve Data
ROIC dropped from -45.57% to -55.79%, capital efficiency is deteriorating. Negative free cash flow of -$29M. The business is consuming cash, not generating it.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
$0.00
Net Income (TTM)
-$35M
▼ -34.0% YoY
Op. Margin
—
ROIC
-55.79%
▼ -10.2pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$31M
▼ -31.7% YoY
Op. Cash Flow (TTM)
-$29M
▼ -28.0% YoY
Net Debt
-$60M
Net Cash Position
Cash & Equiv.
$60M
Continue Research
DiaMedica Therapeutics (DMAC)'s valuation is best read against its own history, its peers, and the growth its price implies. A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, DiaMedica Therapeutics scores 10/100 on Intrinsiqq's quality scorecard (a lower-quality business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from SEC filings; read the full . This is analysis, not investment advice.
DiaMedica Therapeutics scores 10 out of 100 on Intrinsiqq's quality score, a weighted blend of 4 metrics each scored 0 to 100, which makes it a lower-quality business on these measures. Recent fundamentals include a -55.8% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
That depends on valuation and quality together, not either alone. you should weigh DMAC's valuation and scores 10/100 on quality (lower-quality). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.